Figure 1.
Figure 1. OS following treatment with brentuximab vedotin. OS was analyzed using Kaplan–Meier methodology and is shown by best response. All censored patients are indicated by dots on the Kaplan–Meier curve. Reprinted from Gopal AK, Blood, 2015;125(8):1236-1243. Copyright (2015) The American Society of Hematology. Reprinted with permission.2

OS following treatment with brentuximab vedotin. OS was analyzed using Kaplan–Meier methodology and is shown by best response. All censored patients are indicated by dots on the Kaplan–Meier curve. Reprinted from Gopal AK, Blood, 2015;125(8):1236-1243. Copyright (2015) The American Society of Hematology. Reprinted with permission.

Close Modal

or Create an Account

Close Modal
Close Modal